NPI 1548612807: Open Payments
NPI 1548612807. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$821 in 35 payments from 10 companies in 2025. Trend: 2023 $261 · 2024 $421 · 2025 $821
Food & beverage: $756Education: $45Speaker / faculty: $20
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $321 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $157 |
| Novo Nordisk Inc | 3 | $67 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Lilly USA, LLC | 2 | $59 |
| Exact Sciences Corporation | 3 | $57 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| PFIZER INC. | 1 | $24 |
| Becton, Dickinson and Company | 1 | $20 |
| BeOne Medicines USA, Inc. | 1 | $18 |
Products named: BREZTRI, CAPLYTA, FARXIGA, Ozempic, The Cologuard Plus Collection Kit, TRELEGY ELLIPTA, Auvelity, Symbravo.
